|
Clinical Trials for Transitional Cell Carcinoma |
|
|
|
Scottish Terriers, West Highland White Terriers and Shetland Sheepdogs with bladder cancer
Eligibility Requirements
One of the following:
• Confirmed TCC.
• Over 5 years of age
Study Objective
This pilot study is to determine the antitumor effects and the toxicity of a folate‐targeted therapy. The goal is to selectively deliver the chemotherapy inside the tumor cells while limiting the exposure to normal cells.
Compensation
None. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Toceranib Phosphate (Palladia®) for the Treatment of Canine Transitional Cell Carcinoma
Eligibility Requirements
• Dogs with TCC who have had tumor progression while receiving non-steroidal anti-inflammatory drugs (NSAID). Dogs must have a measurable tumor on abdominal ultrasounds.
Study Objective
Transitional cell carcinoma (TCC) is one of the most common cancers of the canine urinary tract. Existing treatment options for this disease have resulted in only modest benefit. Studies in both humans and dogs suggest tyrosine kinase inhibitors can provide a benefit in controlling disease progression for various solid tumors. Toceranib phosphate (Palladia®, Pfizer) is a FDA approved multi-targeted tyrosine kinase inhibitor for dogs with mast cell tumor. The purpose of this study is to evaluate the safety and potential efficacy (tumor response) of toceranib phosphate in management of canine transitional cell carcinoma.
Compensation
The owner is financially responsible for all tests that determine if the patient qualifies for the study. These tests may include abdominal ultrasounds, chest X-rays, blood and urine tests. This study covers the cost of a limited number and portion of re-check examination fees, pre-treatment CBC/platelet counts, abdominal ultrasounds, and chemistry profiles. Toceranib phosphate will be provided to the owner at no charge. Please click on the link for more details.
Location of Trial
North Grafton, MA
More information
Scottish Terriers with transitional cell carcinoma of the bladder.
Eligibility Requirements
• This study is currently only recruiting Scottish Terriers with transitional cell carcinoma of the bladder. Dogs must be feeling well and have adequate bloodwork parameters to participate. No prior treatment for the cancer is permitted, including treatment with non-steroidal anti-inflammatories (NSAIDs) such as piroxicam.
Study Objective
A pilot study to assess feasibility of tissue collections and molecular profiling for future comparative oncology personalized medicine studies.
Compensation
Clients participating in this trial will be given special financial considerations. Specifically, all of the costs associated with the study procedures will be covered, and the client will be given $1000 upon completion of the study to put towards further treatment. Please click on the link for more details.
Location of Trial
Davis, CA
More information
A Pilot Study of Vinblastine/Palladia Therapy for Canine Transitional Cell Carcinoma
Eligibility Requirements
To qualify for enrollment in this study, dogs must have:
• Measurable TCC of the urinary bladder;
• Age > 1 year;
• A life expectancy of at least 16 weeks;
• No evidence of other illness such as kidney, liver or heart disease;
• Not been treated previously with chemotherapy. Previous treatment with NSAIDs and surgery are accepted
Study Objective
To assess efficacy of Palladia and Vinblastine combined for treatment of canine transitional cell carcinoma and to compare computerized tomography and ultrasound for measurement of tumor response.
Compensation
The study will cover the majority of the cost associated with the visits ( around $4500 per patient for the total duration of the study). Palladia will be provided free of charge for 6 months after the study is completed. Owner is responsible for the initial office visit and screening tests, which is estimated to cost $45. For each treatment visit the owners are responsible for $57 (hospital and recheck fees). Please click on the link for more details.
Location of Trial
Columbus, OH
More information
Study NA Pilot Study to Assess Feasibility of Tissue Collections and Molecular Profiling for future Comparative Oncology Personalized Medicine
Eligibility Requirements
One of the following:
• Scottish terriers with transitional cell carcinoma of the bladder
• Golden retrievers with multi-centric lymphoma
• American cocker spaniels with oral melanoma
• creatinine > 3.0
• bilirubin > 2.0 or elevated bile acids
• HCT < 25%, platelets < 50,000
• any >grade 2 hematologic/biochemical abnormality
Study Objective
A pilot study in pet dogs with cancer is needed to determine the feasibility of tissue collection, clinical utility, and large-scale target interrogation across a multi-institutional setting. Data from this feasibility study will inform the design of a personalized therapeutic intent trial in pet dogs. Future comparative oncology modeling of novel personalized medicine strategies will hopefully progress the field and translate into more efficient targeted therapy prescriptions for human cancer patients.
Compensation
Please contact NCI for further information.
Location of Trial
Colorado State University
Purdue University
Tufts University
University of California at Davis
University of Florida
University of Georgia
University of Guelph
University of Michigan
University of Pennsylvania
University of Tennessee
University of Wisconsin
More information
Transitional Cell Carcinoma
Eligibility Requirements
• dog or cat with confirmed Transtitional Cell Carcinoma
Study Objective
To determine if the low dose chemotherapy can destroy transitional cells and/or stabilize the tumor
Compensation
Non-funded study. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Transitional Cell Carcinoma Imaging Study
Eligibility Requirements
• Dog or cat with confirmed Transitional Cell Carcinoma
Study Objective
To determine the viability of 2D-vs-3D-vs-Ct imaging.
Compensation
Funding available on a case by case bases. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Treatment of Transitional Cell Carcinoma with Folates
Eligibility Requirements
• Dog or cat with confirmed Transitional Cell Carcinoma, must be confirmed with a tissue biopsy.
• Animals increased Liver and or Kidney values or any other concurrent disease is not eligible for this study
Study Objective
To determine if the chometherpy delivered with folates increases the efficacy of the chemotherapy alone.
Compensation
Fully Funded. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Transitional Cell Carcinoma Tissue Study
Eligibility Requirements
• Any dog or cat with confirmed TCC
• owner consent for a postmortem autopsy and tissue harvest.
Study Objective
To determine if Transitional cell carcinoma markers are identifiable.
Compensation
Fully funded. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Tavocept use to mitigate nephrotoxicity associated with cisplatin and piroxicam treatment of canine bladder cancer
Eligibility Requirements
• Measureable confirmed TCC of the urinary bladder
• No previous chemotherapy, radiation therapy or excisional surgery for TCC
• NSAID’s must be discontinued for at least 14 days prior to study enrollment
• Adequate renal function-normal creatinine and BUN on VMTH panel and adequate urine specific gravity.
• No serious or life –threatening concurrent disease reducing life expectancy to < 16 weeks
• PCV > 25%, neutrophil count > 2500/ul, platelet count > 100,000
• Initial: CBC, UA, serum creatinine and BUN, thoracic rads, abdominal ultrasound/rads, abdominal CT.
Study Objective
The purpose of this study is to evaluate the efficacy of Tavocept in preventing drug-induced toxicity (especially nephrotoxicity) associated with cisplatin and piroxicam therapy for canine bladder cancer and to demonstrate that administration of Tavocept prior to cisplatin chemotherapy in tumor-bearing dogs facilitates the safe use of a shortened diureses protocol as is the case in people. The overall study goal is to develop a safer (non-nephrotoxic) and more efficacious treatment regimen for dogs with TCC of the urinary bladder by the use of the novel cytoprotective and antitumor potentiating agent, Tavocept.
Compensation
Treatment provided at no cost to the owner. This includes initial staging and follow-up CT scans and abdominal ultrasounds, blood work done at the VMTH, radiographs, chemotherapy, hospitalization and subsequent office visits at recheck exams. . Please click on the link for more details.
Location of Trial
Colombia, MO
More information
Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Label Dosing
Eligibility Requirements
• Have a sarcoma, carcinoma, melanoma or other solid tumor (excluding histiocytic sarcoma and hemangiosarcoma) that has either failed standard therapy or for which the owner declines standard therapy
• Have a life expectancy of approximately 90 days
• Have completed any chemotherapy or radiation therapy at least 2 weeks prior to enrollment
Study Objective
The goal of this study is to determine the pharmacokinetics (blood levels) of Palladia given to dogs with cancer at doses lower than that recommended on the label.
Compensation
Palladia will be provided at no cost during, and 6 months after the completion of the study representing a savings of $1500-3000 to owners. The owner is responsible for all other costs including office visits and bloodwork. Please click on the link for more details.
Location of Trial
Columbus, Ohio
More information
Transitional cell carcinoma study in dogs
Eligibility Requirements
• Dogs of the following breeds: Highland White Terrier, Scottish Terrier, Shetland Sheep Dog or Beagle that is over the age of 7
o Either affected (has bladder cancer) OR
o Unaffected (does not have bladder cancer)
Study Objective
To determine the cause of bladder cancer West Highland White Terriers, Scottish Terriers, Shetland Sheep dogs and Beagles.
Compensation
This study is not funded. Please click on link for more details.
Location of Trial
East Lansing, MI
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Liposomal clodronate in canine cancer (excluding mast cell tumor, hemangiosarcoma and malignant histiocytosis)
Eligibility Requirements
• Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcom and malignant histiocytosis) are potentially eligible
• The tumor must be less than 8cm (approximately 3.5 inches) in diameter and located in an easily accessible area for biopsy.
• Dogs must have good function of liver and kidneys and acceptable blood cell counts.
• Dogs must be free of underlying disease.
• OWNERS MUST CONSENT TO A POSTMORTEM EXAM (AUTOPSY) AT THE TIME THEIR PET DIES OR IS EUTHANIZED.
Study Objective
The goals of this study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor activity of liposomal clodronate against a variety of canine tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Fort Collins, CO
More information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
|
| |
|
